Salmonella biofilm protein causes autoimmune responses—possible link with Alzheimer’s, Parkinson’s
Scientists from VIDO-InterVac and Temple University in Philadelphia, Penn., have demonstrated that a salmonella biofilm protein can cause autoimmune responses and arthritis in animals.
Promising pre-clinical results for USask VIDO-InterVac COVID-19 vaccine
A COVID-19 vaccine candidate developed by VIDO-InterVac has cleared another major milestone in moving towards human clinical trials: the novel vaccine has proven highly effective in ferrets, one of the commonly used animal models for COVID-19.
USask’s VIDO-InterVac and the National Research Council of Canada collaborate to advance development of vaccine against COVID-19
VIDO-InterVac and NRC announced a collaboration to accelerate the development and production of a candidate COVID-19 antigen in mammalian cells.
ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19
ZYUS Life Sciences Inc. and VIDO-InterVac will collaborate to test plant produced antigens in a vaccine for COVID-19.
USask VIDO-InterVac awarded $23M for COVID-19 vaccine research
VIDO-InterVac has been awarded $23 million to fast-track efforts to develop a COVID-19 vaccine, Prime Minister Justin Trudeau announced today.
Prime Minister announces new support for COVID-19 medical research and vaccine development
$23 million announced to accelerate development of a vaccine against COVID-19. Funding will support pre-clinical testing and clinical trials of a potential COVID-19 vaccine, essential steps to ensuring that vaccines are effective and safe for human use.
SHA and VIDO-InterVac partner to help ensure supply of N95 respiratory masks
The Saskatchewan Health Authority and VIDO-InterVac at the University of Saskatchewan are partnering on a way to safely decontaminate and reuse N95 respiratory masks that are normally thrown away after each use.
USask VIDO-InterVac and International Vaccine Institute collaborate on COVID-19 work
IVI of South Korea, a world-renowned international organization founded by the United Nations Development Programme, is collaborating with VIDO-InterVac to better understand the virus causing COVID-19 and to develop vaccines and potential treatments.
Saskatchewan government invests $3.6M in USask COVID-19 vaccine research
The Government of Saskatchewan has announced $3.6 million in new funding for VIDO-InterVac one of the world’s most advanced infectious disease labs and a leader in global efforts to find a COVID-19 vaccine.
New Money Aids Saskatchewan’s Search For Covid-19 Vaccine
The Government of Saskatchewan and the Federal Government are committing $28 million to VIDO-InterVac to develop a vaccine for COVID-19.